Introduction {#S1}
============

The dissemination of multidrug-resistant (MDR) bacteria is a recognized worldwide problem in both human and veterinary medicine ([@B1]). Among MDR strains, extended spectrum ß-lactamase (ESBL) producing *Klebsiella pneumoniae* are frequently implicated in nosocomial infections thus, not surprisingly, being considered by the World Health Organization as a major global concern ([@B41], [@B42]).

*K. pneumoniae* is considered a commensal agent in horses and its clinical relevance and disease severity depend on the strain's pathogenic potential ([@B33]). Additionally, horses have been shown to carry human associated MDR *K. pneumoniae* ([@B11]) and ESBL-producing bacteria, but characterization of MDR isolates are still lacking for this particular species ([@B20]), with only a few reports of ESBL-producing *K. pneumoniae* in horses available to date ([@B34]; [@B11]; [@B36]).

Evidence is growing on the importance of shared MDR bacterial populations between humans and other animals such as companion animals ([@B11]; [@B13]), livestock ([@B9]), or wildlife ([@B26]), including ESBL-producing strains ([@B37]). The misuse of antimicrobials in animals, has led the World Health Organization to develop in 2017 guidelines to minimize the administration of critical antibiotics to food producing animals. However, Portugal still remains one of the countries with the highest antimicrobial consumption per animal population (mg/PCU) in Europe (4th out of 30 countries; [@B10]) This is worrying, since it imposes a selection pressure on pathogenic, commensal and environmental bacteria that could lead to the maintenance and recruitment of resistance genes ([@B6]). It is known that bacteria isolated from horses share common genetic ground with other animals and human isolates ([@B27]) and this supports the hypothesis that these animals are likely to have a particular role in antimicrobial resistance transmission. Therefore, efforts to better understand the role of horses as carriers of such pathogens are of major importance to public health.

In this study, we characterized an ESBL-producing *K. pneumoniae* sequence type (ST) 348 isolate from a horse by whole genome sequencing (WGS). Additionally, we compared this strain to ST348 human isolates previously obtained and characterized, in order to assess the genetic relationship between *K. pneumoniae* ST348 isolates from Portugal.

Materials and Methods {#S2}
=====================

Sample Collection and Epidemiological Data {#S2.SS1}
------------------------------------------

A 14-year-old Lusitano horse with signs of abdominal pain was referred to a referral equine hospital in Lisbon in June 2016 and diagnosed with a small intestinal inguinal hernia. Laparotomy was performed, and the incarcerated portion of non-viable small intestine was resected under general anesthesia. The horse had never been subjected to antimicrobial therapy before and was treated with penicillin at a dose of 22 000 UI/kg for 7 days and gentamicin at a dose of 6,6 mg/kg for 5 days post-surgery. The patient developed a surgical site infection of the abdominal wall that was detected on day 4 post-surgery. A swab sample was collected from the site and further streaked in Blood and MacConkey agar. After a 24 h incubation at 37°C, pure bacterial cultures were obtained, posteriorly identified as *K. pneumoniae* using API 20 *E* test (Biomérieux, Marcy-Étoile, France).

The Laboratory of Microbiology of the Faculty of Pharmacy of the University of Porto provided the seven ST348 human isolates ([@B22], [@B24] and unpublished data).

Antimicrobial Susceptibility Profile {#S2.SS2}
------------------------------------

The isolates susceptibility profile was determined with the Vitek 2 system, using the AST N344 card. The minimal inhibitory concentration (MIC) for ciprofloxacin was determined using *E*-test, following EUCAST breakpoint guidelines ([@B31]).

Whole Genome Sequencing and Data Analysis {#S2.SS3}
-----------------------------------------

Whole genome sequencing of all isolates was performed. DNA extraction was performed with the DNeasy UltraClean Microbial Kit (Qiagen, Hilden, Germany) and DNA concentration was measured with a Qubit 2.0 fluorometer (Life Technologies, Thermo Fisher Scientific, Waltham, MA, United States).

The DNA was then diluted to 0.2 ng/μl and 1 ng was used for the library preparation, using the Nextera XT Library Preparation kit (Illumina, CA, United States), according to the manufacturer's protocol. DNA was sequenced using the Miseq (Illumina) generating 2 times 250-bp reads and *de novo* assembly was done by CLC Genomics Workbench v11.0 (Qiagen) after quality (Phred scores \>30) and adapter trimming. Annotation was performed using the RAST server^[1](#footnote1){ref-type="fn"}^. Resistome analysis was performed by uploading sequences to the CGE server^[2](#footnote2){ref-type="fn"}^. Plasmid replicons were identified through Abricate v0.8-dev^[3](#footnote3){ref-type="fn"}^, while the ST, *wzi*, K and O types and a virulence score, based on the presence or absence of different siderophores genes and a genotoxin gene, were determined through Kleborate v0.2.0^[4](#footnote4){ref-type="fn"}^ and Kaptive v0.5.1^[5](#footnote5){ref-type="fn"}^.

For MinION long-reads, base calling and demultiplexing was performed using Albacore v1.2.2 (ONT) and data quality was analyzed through Poretools v0.6.0 ([@B19]). Adapter trimming was attained through Porechop v0.2.3^[6](#footnote6){ref-type="fn"}^. Hybrid assemblies of short- and long-reads were performed using Unicycler v0.4.1 ([@B38]). Bandage v0.8.1 ([@B39]) was used to visualize the assembly graphics. Easyfig was used to compare plasmids pK1 and pDA33141-217 ([@B30]). BRIG was used to align plasmid pK1 with the assemblies of the human strains ([@B3]).

The comparative phylogenetic analysis of the eight isolates was performed using a core genome (cg) MLST approach through Ridom SeqShere+ software (Ridom, Munster, Germany) and BacWGSTdb was used to perform a comparison with similar isolates ([@B25])^[7](#footnote7){ref-type="fn"}^.

Amino-acid substitutions were investigated in the quinolone resistance determining regions (QRDR) of the *gyrA*, *gyrB*, *parC*, and *parE* genes.

Results {#S3}
=======

MDR *Klebsiella pneumoniae* ST348 in a Horse {#S3.SS1}
--------------------------------------------

The *K. pneumoniae* isolate obtained from the surgical site infection was resistant to the majority of the antimicrobials tested, which included different cephalosporins, fluoroquinolones and aminoglycosides ([Table 1](#T1){ref-type="table"}). WGS allowed the analysis of its resistome, revealing the presence of *bla*~CTX--M--15~, among several other resistance genes ([Table 2](#T2){ref-type="table"}). The complete sequence of a large plasmid was obtained through a combination of long- and short-read sequencing (∼190 kb), which carried several antimicrobial resistance genes (*bla*~CTX--M--15~, *bla*~TEM--1B~, *bla*~OXA--1~, *sul2*, *aph(6)-Id*, *aac(6′)-Ib-cr*, *catB4*, *tet*(A), *dfrA14*, *qnrB1*) and genes associated with metal tolerance (*ars* operon). Replicons from incompatibility groups IncFII and IncFIB were identified. A comparison between our plasmid pK1 and pDA33141-217, the closest plasmid in the Genbank database (CP029588; homology \<99%, sequence cover \<83%) was performed, and differences are mainly due to rearrangements in the region surrounding the *bla*~CTX--M--15~ gene. By using a BLAST approach, a similar plasmid was also found in the human strain 122.1, but not in the other human ST348 isolates.

###### 

Susceptibility profile of the horse *K. pneumoniae* strain K.

  **Phenotypic resistance**               **Breakpoint (mg/L)**           
  ------------------------------- ------- ----------------------- ------- -------
  Ampicillin                      ≥32     R                       ≤8      \>8
  Amoxicillin/clavulanic acid     ≥32     R                       ≤8      \>8
  Piperacillin/tazobactam         32      R                       ≤8      \>16
  Cefuroxime                      ≥64     R                       ≤8      \>8
  Cefoxitin                       ≤4      S                       ≤8      \>8
  Cefotaxime                      ≥64     R                       ≤1      \>2
  Ceftazidime                     32      R                       ≤1      \>4
  Imipenem                        ≤0.25   S                       ≤2      \>4
  Meropenem                       ≤0.25   S                       ≤2      \>8
  Gentamicin                      ≥16     R                       ≤2      \>4
  Tobramycin                      ≥16     R                       ≤2      \>4
  Ciprofloxacin                   ≥4      R                       ≤0,25   \>0,5
  Fosfomycin                      ≤16     S                       ≤32     \>32
  Nitrofurantoin                  128     R                       ≤64     \>64
  Colistin                        ≤0.5    S                       ≤2      \>2
  Trimethoprim                    ≥16     R                       ≤2      \>4
  Sulfamethoxazole/trimethoprim   ≥16     R                       ≤2      \>4

###### 

Antimicrobial resistance genes of the horse *K. pneumoniae* strain K.

                                                                **Enzyme**     
  ----------------- ------------------- -------- -------------- -------------- -------------------------------------------------
  ß-Lactams         *bla*~TEM--1--B~    100.00   JF910132       TEM-1B         Penicillinase
                    *bla*~SHV--11~      99.88    EF035557       SHV-11         Penicillinase
                    *bla*~OXA--1~       100.00   J02967         OXA-1          ESBL
                    *bla*~CTX--M--15~   100.00   DQ302097       CTX-M-15       ESBL
  Aminoglycosides   *aac(6′)-Ib-cr*     100.00   DQ303918       AAC(6′)Ib-cr   Acetyltransferase
                    *aph(3")-Ib*        100.00   AF321551       APH(3")-Ib     Phosphotransferase
                    *aph(6)-Id*         100.00   M28829         APH(6)-Id      Phosphotransferase
                    *aac(3)-IIa*        99.77    X51534         AAC(3)-IIa     Acetyltransferase
  Fosfomycin        *fosA*              99.52    ACWO01000079   FosA           Mn2+ and K+-dependent glutathione S-transferase
  Phenicols         *catB4*             100      EU935739       CatB4          Acetyltransferase
  Quinolones        *oqxB*              99.08    EU370913       OqxB           Efflux
                    *oqxA*              99.15    EU370913       OqxA           Efflux
                    *aac(6′)-Ib-cr*     100.00   DQ303918       AAC(6′)Ib-cr   Acetyltransferase
                    *qnrB1*             100      Q351241        QnrB1          Topoisomerase type II protection
  Sulfonamides      *sul2*              100.00   GQ421466       Sul1           Efflux
  Tetracyclines     *tet(A)*            100.00   AJ517790       TetA           Efflux
  Trimethoprim      *dfrA14*            99.59    DQ388123       DfrA12         Dihydrofolate reductase

Comparative Analysis With Human Isolates {#S3.SS2}
----------------------------------------

A comparative analysis with other MDR *K. pneumoniae* ST348 isolated from humans in Portugal between 2012 and 2016 was performed to evaluate a possible genetic link. These human isolates were obtained as colonizers or causing infection in individuals in long-term health care facilities and hospitals, and produced CTX-M-15 and occasionally KPC-3 ([@B22], [@B24]; [Table 3](#T3){ref-type="table"}). As in the equine isolate, the same ST capsular type, KL62 (*wzi*94), and O1v1 antigen, were found. In addition, all isolates had similar content on ß-lactamases genes (*bla*~CTX--M--15~, *bla*~SHV--11~, *bla*~OXA--1~, and/or *bla*~TEM--1~), with differences for isolate Kp56 that had a carbapenemase gene, *bla*~KPC--3~, isolate 102-1 that lacked the *bla*~OXA--1~ gene, and isolate C1685 that lacked the *bla*~TEM--1B~ gene ([Table 4](#T4){ref-type="table"}). Additionally other antimicrobial resistance genes were also present in all isolates \[*aac(6′)-Ib-cr*, *fosA*, *catB4*, *oqxA*, and *oqxB* ([Table 4](#T4){ref-type="table"})\]. All of them carried the FIB replicon, but variably the repFII or repFIA. The isolates were also analyzed concerning their virulence score, which, according to the score system provided by Kleborate, was 1 out of 5 for the isolates that contained the yersiniabactin gene, and 0 out of 5 for the only isolate in which this gene was not detected.

###### 

Epidemiological and genetic features of the eight *K. pneumoniae* ST348 isolates studied.

                        **C1682**                         **C1685**                        **C1741**                         **Kp56**                                 **K107**                          **102-1**                         **122-1**                         **K**
  --------------------- --------------------------------- -------------------------------- --------------------------------- ---------------------------------------- --------------------------------- --------------------------------- --------------------------------- -----------------------------------
  Sequence type (ST)    ST348                             ST348                            ST348                             ST348                                    ST348                             ST348                             ST348                             ST348
  wzi                   *wzi94*                           *wzi94*                          *wzi94*                           *wzi94*                                  *wzi94*                           *wzi94*                           *wzi94*                           *wzi94*
  K antigen             KL62                              KL62                             KL62                              KL62                                     KL62                              KL62                              KL62                              KL62
  O antigen             O1v1                              O1v1                             not identified                    O1v1                                     O1v1                              O1v1                              O1v1                              O1v1
  Plasmid Inc., Group   IncFII, IncFIB                    IncFIB                           IncFII, IncFIB                    IncFII, IncFIA, IncFIB                   IncFII, IncFIB                    IncFII, IncFIB                    IncFIB                            IncFII, IncFIB
  ß-lactamases genes    CTX-M-15, SHV-11, OXA-1, TEM-1B   CTX-M-15, SHV-11, OXA-1          CTX-M-15, SHV-11, OXA-1, TEM-1B   KPC-3, CTX-M-15, SHV-11, OXA-1, TEM-1B   CTX-M-15, SHV-11, OXA-1, TEM-1B   CTX-M-15, SHV-11, TEM-1B          CTX-M-15, SHV-11, OXA-1, TEM-1B   CTX-M-15, SHV-11, OXA-1, TEM-1B
  Source (Age/Gender)   Urine/UTI, Human (82/M)           Urine/UTI, Human (81/M)          Exudate/SSTI, Human (72/M)        Urine/UTI, Human (87/M)                  Human (F)                         Rectal swab, Human (F/89)         Rectal swab, Human (M/79)         SSI, Horse (M/14)
  Date of isolation     14/08/12                          18/08/12                         20/09/12                          03/10/14                                 07/10/15                          07/01/16                          07/01/16                          16/06/16
  Place of isolation    Community Lab, North, Portugal    Community Lab, North, Portugal   Community Lab, North, Portugal    Household resident, Oporto, Portugal     Hospital, Oporto, Portugal        LTCF resident, Oporto, Portugal   LTCF resident, Oporto, Portugal   Equine Hospital, Lisbon, Portugal

F, female; M, male; SSI, Surgical Site Infection; SSTI, Skin and Soft Tissue Infection; and UTI, Urinary Tract Infection.

###### 

Resistance genes found in the eight *K. pneumoniae* ST348 isolates.

                      **C1682**             **C1685**   **C1741**             **Kp56**   **K107**              **102-1**   **122-1**             **K**                                                                                                                       
  ------------------- --------------------- ----------- --------------------- ---------- --------------------- ----------- --------------------- -------- --------------------- -------- --------------------- -------- --------------------- -------- --------------------- --------
  ß-Lactams           *bla*~*TEM--1--B*~    100.00      *bla*~*SHV--11*~      99.88      *bla*~*TEM--1--B*~    100.00      *bla*~*TEM--1--B*~    100.00   *bla*~*TEM--1--B*~    100.00   *bla*~*TEM--1--B*~    100.00   *bla*~*TEM--1--B*~    100.00   *bla*~*TEM--1--B*~    100.00
                      *bla*~*SHV--11*~      99.88       *bla*~*OXA--1*~       100.00     *bla*~*SHV--11*~      99.88       *bla*~*SHV--11*~      99.88    *bla*~*SHV--11*~      99.88    *bla*~*SHV--11*~      99.88    *bla*~*SHV--11*~      99.88    *bla*~*SHV--11*~      99.88
                      *bla*~*OXA--1*~       100.00      *bla*~*CTX--M--15*~   100.00     *bla*~*OXA--1*~       100.00      *bla*~*OXA--1*~       100.00   *bla*~*OXA--1*~       100.00   *bla*~*CTX--M--15*~   100.00   *bla*~*OXA--1*~       100.00   *bla*~*OXA--1*~       100.00
                      *bla*~*CTX--M--15*~   100.00                                       *bla*~*CTX--M--15*~   100.00      *bla*~*CTX--M--15*~   100.00   *bla*~*CTX--M--15*~   100.00                                  *bla*~*CTX--M--15*~   100.00   *bla*~*CTX--M--15*~   100.00
                                                                                                                           *blaKPC-3*            100.00                                                                                                                      
  Aminogly -cosides   *aac(6′)-Ib-cr*       100.00      *aac(6′)-Ib-cr*       100.00     *aac(6′)-Ib-cr*       100.00      *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00
                      *aph(3″)-Ib*          100.00                                       *aph(3″)-Ib*          100.00      *aph(3″)-Ib*          100.00   *aph(3″)-Ib*          100.00   *aph(3″)-Ib*                   *aph(3″)-Ib*          100.00   *aph(3″)-Ib*          100.00
                      *aph(6)-Id*           100.00                                       *aph(6)-Id*           100.00      *aph(6)-Id*           100.00   *aph(6)-Id*           100.00   *aph(6)-Id*           100.00   *aph(6)-Id*           100.00   *aph(6)-Id*           100.00
                      *aac(3)-IIa*          100.00      *aac(3)-IIa*          100.00     *aac(3)-IIa*          100.00      *aac(3)-IIa*          100.00   *aac(3)-IIa*          100.00                                  *aac(3)-IIa*          100.00   *aac(3)-IIa*          99.77
  Fosfomycin          *fosA*                99.52       *fosA*                99.52      *fosA*                99.52       *fosA*                99.52    *fosA*                99.52    *fosA*                99.52    *fosA*                99.52    *fosA*                99.52
  Phenicols           *catB4*               100.00      *catB4*               100.00     *catB4*               100.00      *catB4*               100.00   *catB4*               100.00   *catB4*               100      *catB4*               100      *catB4*               100
  Quinolones          *oqxB*                99.08       *oqxB*                99.08      *oqxB*                99.08       *oqxB*                99.08    *oqxB*                99.08    *oqxB*                99.08    *oqxB*                99.08    *oqxB*                99.08
                      *oqxA*                99.15       *oqxA*                99.15      *oqxA*                99.15       *oqxA*                99.15    *oqxA*                99.15    *oqxA*                99.15    *oqxA*                99.15    *oqxA*                99.15
                      *aac(6′)-Ib-cr*       100.00      *aac(6′)-Ib-cr*       100.00     *aac(6′)-Ib-cr*       100.00      *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00   *aac(6′)-Ib-cr*       100.00
                      *qnrB1*               99.07                                        *qnrB1*               99.07       *qnrB1*               100.00   *qnrB1*               100.00   *qnrB1*               100.00   *qnrB1*               100.00   *qnrB1*               100
  Sulfonamides                                                                                                                                                                                                          *sul1*                100.00                         
                      *sul2*                100.00                                       *sul2*                100.00      *sul2*                100.00   *sul2*                100.00   *sul2*                100.00   *sul2*                100.00   *sul2*                100.00
  Tetracyclines       *tet(A)*              100.00                                       *tet(A)*              100.00      *tet(A)*              100.00   *tet(A)*              100.00   *tet(A)*              100.00   *tet(A)*              100.00   *tet(A)*              100.00
  Trimethoprim        *dfrA14*              99.59                                        *dfrA14*              99.59       *dfrA14*              99.59    *dfrA14*              99.59    *dfrA14*              99.59    *dfrA14*              99.59    *dfrA14*              99.59

The clonal relatedness was evaluated using a gene-by-gene typing method (core genome Multi-Locus Sequence Typing \[cgMLST\]). Allele differences between the isolates ranged from 4 to 21 in a total of 2358 genes. There were 21 allele differences between the horse isolate (K) and the closest human colonizing isolate (isolate 122-1) obtained from a long term-care facility resident ([Figure 1](#F1){ref-type="fig"}). Using the BacWGSTdb, 56 allele differences between the horse isolate (K) with the closest isolate deposited in the database were detected. Again, this isolate corresponded to a human strain from a respiratory infection in Portugal in 2013.

![Minimum-spanning tree based on cgMLST allelic profiles of 8 *K. pneumoniae* genomes obtained through WGS. Each circle represents an allelic profile based on sequence analysis. The numbers on the connecting lines illustrate the numbers of target genes with differing alleles.](fmicb-10-01657-g001){#F1}

*Klebsiella pneumoniae* ST348 QRDR {#S3.SS3}
----------------------------------

Our collection of *K. pneumoniae* ST348 showed no mutations in the QRDR regions, except for two isolates (C1685 and Kp56) that presented a mutation in codon 83 of the *gyrA* gene. MIC results to ciprofloxacin ranged from 0.75 mg/L to 8 mg/L. One isolate (K107) presented high resistance to ciprofloxacin, with an MIC of \>32 mg/L.

Discussion {#S4}
==========

MDR *Klebsiella pneumoniae* ST348 in a Horse {#S4.SS1}
--------------------------------------------

According to the Centers for Disease Control and Prevention (CDC), complications or infections secondary to either device implantation or surgery are referred to as hospital-acquired infections ([@B7]). Acquisition of infections within the hospital are silent threats, especially when the source remains unknown ([@B36]). This horse developed a surgical site infection due to a MDR *K. pneumoniae* during hospitalization, which was therefore considered a hospital-acquired infection. We do not know if the contamination source was exogenous (i.e., surgical personnel) or intrinsic (i.e., horse's skin) and if it was developed during, or after surgery. However, a recent study showed that a positive intra-operative culture was not a predictor of SSI; and even when a SSI did occur, it may be due to a different bacterial isolate ([@B15]). The occurrence of ESBL-producing bacteria in horses ([@B16]; [@B4]), including isolates containing the *bla*~CTX--M--15~ gene ([@B17]), has been shown in previous studies. The challenge of treating such infections can be overcome by the use of antiseptics ([@B29]) without the need for treatment with antimicrobials. This was the case in this patient, where the infected wound was successfully treated with lavages using a saline solution containing 0.05% of chlorhexidine, performed twice a day for 1 week ([@B40]).

*K. pneumoniae* ST348 Clones {#S4.SS2}
----------------------------

The isolate obtained from the wound was identified as a *K. pneumoniae* ST348, a ST not previously reported in animals. In addition, it has rarely been identified in international collections and databases of MDR *K. pneumoniae* isolates from humans ([@B5]; [@B8]; [@B25]) or in other hosts ([@B14]), and there is still scarce surveillance data on different non-human niches. Indeed, most reports of ST348 *K. pneumoniae* in humans are from the Northern region of Portugal, where this lineage seems to be circulating since at least 2012 as a CTX-M-15 producer that subsequently acquired KPC-3. The isolates were obtained from community-based patients or residents in long-term care facilities with previous contact to different hospitals, suggesting a more extended dissemination in the country ([@B23], [@B22], [@B24]; [@B35]).

Several studies have associated quinolone resistance to a higher fitness cost and the establishment of major and minor clones in different bacterial species ([@B21]; [@B12]). [@B32] have related a high number of amino-acid substitutions in QRDR with a better fitness *in vitro* and *in vivo* (e.g., major clones) in *K. pneumoniae* species. Results from this study are in accordance with this, as our isolates present no mutations, except for two isolates (C1685 and Kp56) that presented only one mutation. Although these ST348 isolates are CTX-M-15 producers, we hypothesized that this clone is also a minor clone that suffered large fitness cost with the introduction of fluoroquinolones but still acquired alternative mechanisms of resistance {both efflux mediated resistance \[*aac(6′)-Ib-cr*, *oqxA*, and *oqxB* genes\] and *qnr* determinants}, thus being a minor clone with a better fitness adaptation. The MIC results of ciprofloxacin also support this hypothesis as our isolates present MIC's ranging from 0.75 mg/L to 4 mg/L that are lower than those associated with major clones ([@B32]) with two exceptions for isolates C1741 (MIC 8 mg/L), and K107 (MIC \> 32 mg/L), showing that this clone has also a better adaptation to these drugs.

Comparative Analysis With Human Isolates {#S4.SS3}
----------------------------------------

A cgMLST analysis, comparing the horse and human isolates, was performed to detect a possible genetic link that could provide evidence for the source of the *K. pneumoniae* strain ([Figure 1](#F1){ref-type="fig"}). Recent cut-offs advocate that clonal relatedness is accepted for the *K. pneumoniae* isolates when allele difference are less than 10 ([@B28]); using this cutoff we could assume that there is no genetic link between the horse and human isolates. Despite that, other authors have interpreted these cutoffs from a different perspective as they advocate that 16 to 21 allele differences between isolates from carriers from different species suggest that transmission has occurred ([@B2]; [@B18]). Moreover, most of the few studies that define cutoffs for cgMLST analysis are based on human isolates only ([@B28]) and do not take into account interspecies transmission.

A direct clinical epidemiological link between the horse isolate and the human isolates could not be found except for the year of isolation: none of the horses' tutors had contact with hospitals or long-term care facilities in the Northern part of Portugal, where the horse stable was located, and none of the veterinarians and caretakers had been previously infected or known to be colonized with an ESBL-*K. pneumoniae* strain (although active surveillance was not routinely performed). Furthermore, it was not possible to establish the previous colonization of the horse, as samples are usually not collected prior to emergency surgeries.

Taking into consideration the similarities between the horse and human isolates, one can consider the possibility of a silent dissemination of *K. pneumoniae* ST348 amongst humans and horses in Portugal. A direct human-to-animal transmission or a common source of infection cannot be ruled out, especially since active surveillance of MDR pathogens of people in contact with the horse was not performed. The low virulence presented by these isolates and therefore the improbability of the isolation of this particular ST of *K. pneumoniae*, also supports the hypothesis of a silent dissemination. This is also enhanced by the results revealed by the cgMLST analysis performed with BacWGSTdb, since all the *K. pneumoniae* ST348 strains deposited in this database were human strains, the majority from Portugal.

Horses have different uses in today's society, which include sports, leisure, production and consumption. It is very likely that the lack of active surveillance and characterization of antimicrobial resistant bacteria in these animals, and the proximity to man is contributing to the spread and evolution of these MDR strains. This report suggests that some *K. pneumoniae* clones, as the ST348, can carry critical resistance genes and disseminate them in different populations, despite their low virulence.
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